₹ 3,074.18 Cr
1.93%
BSE Healthcare TRI
INF740KA1LD8
100.0
100.0
100
Mr. Chirag Dagli
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| DSP Healthcare Fund - Regular Plan - Growth | -2.26 | 21.91 | 17.67 |
| Benchmark | - | - | - |
Equity
Debt
Others
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. There is no assurance that the investment objective of the Scheme will be achieved
| Company | Holdings (%) |
|---|---|
| CIPLA LIMITED EQ NEW FV RS.2/- | 8.76 |
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 7.96 |
| SUVEN PHARMACEUTICALS LIMITED EQ | 7.9 |
| IPCA LABORATORIES LIMITED EQ NEW FV RE .1/- | 7.39 |
| LAURUS LABS LIMITED EQ NEW FV RS. 2/- | 6.07 |
| GLAND PHARMA LIMITED EQ NEW FV Re.1/- | 5.96 |
| Sai Life Sciences Limited | 4.77 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 4.69 |
| Globus Medical Inc | 4.45 |
| Illumina Inc | 4.4 |
| Sector | Holdings (%) |
|---|---|
| Healthcare | 82.67 |
| Financial Services | 1.48 |
| Consumer Services | 0.47 |